Insider buying last 90 days
No open-market insider purchases were filed for MIRM in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MIRM insider filing, plotted on the chart in Gekko.Open MIRM in Gekko
NASDAQ: MIRM
Mirum Pharmaceuticals (MIRM) Stock Analysis & Forecast
Sep 28 close
$87.96−1.74 (−1.9%)
Gekko Brief
AI summaryMirum Pharmaceuticals draws attention this week on regulatory and clinical news. The FDA approved Atebrioz (zilurgisertib), developed with Incyte, for Fibrodysplasia Ossificans Progressiva in patients aged 12 and older, backed by PROGRESS data showing a reduction in new HO lesion volume. Separately, the company reported that its Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta met its primary endpoint, with the experimental drug lowering virus levels in patients in the late-stage trial. Mirum also hosted an investor call to discuss the topline results, and MarketBeat noted an average target price of $137.31 from fifteen analysts.
Shares closclose at $87.96, down 1.9%, sitting between the 50-day average of $100.65 and the 200-day average of $97.85, with a one-month return of -11.8% and a three-month return of -28.5%. The GekkoIndex reads 70.1, placing the stock in the Buying zone. Price stands 24.1% below Gekko Fair Value of $115.95.
Earnings are scheduled for 3 November 2026 after close, 35 days out, beyond a typical 20-day hold. No insider, Congress or unusual options activity appears in their respective windows. Consensus among 10 firms is Buy, with a consensus target of $138.21, implying 57.1% upside. Seasonality over the next 20 trading days has averaged -6% across 5 years, rising in 2 of them, a pattern worth noting alongside the current gap to fair value.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Mirum Pharmaceuticals price vs fair value
Close $87.96200-day averageGekko Fair Value $115.95
Mirum Pharmaceuticals quick facts
- Market cap
- $5.36B
- P/E ratio
- —
- Forward P/E
- 166.7
- EPS, TTM
- −$14.09
- Revenue, TTM
- $618.1M
- Profit margin
- -139.2%
- Dividend yield
- —
- Beta
- 0.49
- Volume
- 1.24M avg 712,292
- 1-year return
- +19.6%
- Typical daily move
- ±4.7%
- Typical 20-day move
- ±8.7%
- 50-day average
- $100.65
- 200-day average
- $97.85
- Next earnings
- Nov 3 after close
- Shares outstanding
- 64.93M
Mirum Pharmaceuticals swing-trade checklist
Mirum Pharmaceuticals scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $87.96 sits between the 50-day ($100.65) and 200-day ($97.85) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
70.1, Buying
Reading 70.1 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
24.1% below
Price is 24.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 35 days
Next report Nov 3, 2026, 35 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−6.0% on average
From this point in the calendar, the next 20 trading days averaged −6% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Mirum Pharmaceuticals stock chart and price history
Mirum Pharmaceuticals closed at $87.96 on Sep 28, 2026, +19.6% over the past year, inside a 52-week range of $63.23 to $130.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −11.8%
- 3 months
- −28.5%
- 6 months
- −0.5%
- 1 year
- +19.6%
The full MIRM chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MIRM in Gekko
Follow Mirum Pharmaceuticals through every session
Put MIRM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MIRM in GekkoFree for 7 days. No credit card required.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals works on medicines meant for patients facing uncommon and severely underserved illnesses, with much of its attention on disorders of the liver. The company is most recognized for LIVMARLI, a treatment taken by mouth that is being tested against progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia.
Alongside this, Mirum is also moving forward with Volixibat, aimed at treating intrahepatic cholestasis that occurs during pregnancy as well as primary sclerosing cholangitis. These two programs make up the main focus of what the company is building toward, as it works to turn early-stage research into approved treatments for people living with these conditions.
Mirum Pharmaceuticals traces its founding to 2018 and keeps its base in Foster City, California. Its stock trades on the NASDAQ exchange under the symbol MIRM.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- mirumpharma.com
Mirum Pharmaceuticals GekkoIndex: the smart money zone
Mirum Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 70.1, in the Buying zone, up 0.7 points over five sessions.
70.1Buying
Up 0.7 points over five sessions, from the Accumulation zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 10 | +1.2% | +9.7% | ||
| Accumulation | 205 | +1.1% | +5.7% | ||
| Neutral | 387 | +0.9% | +4.7% | ||
| Distribution | 62 | +2.4% | +1.7% | ||
| Selling | 8 | Too few readings yet | |||
Average MIRM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.2% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the MIRM price, zone by zone.Track MIRM in Gekko
Is Mirum Pharmaceuticals stock overvalued? Gekko Fair Value
Mirum Pharmaceuticals trades 24.1% below Gekko Fair Value of $115.95, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Mirum Pharmaceuticals shares are worth, recalculated every trading day.
$115.95
Gekko Fair Value, Sep 26, 2026
24.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open MIRM in Gekko
Mirum Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Mirum Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in MIRM were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for MIRM, plotted on the chart in Gekko.Open MIRM in Gekko
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold MIRM.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Mirum Pharmaceuticals earnings: next date and track record
Mirum Pharmaceuticals reports on Nov 3, 2026, after the close (35 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected after the close, 35 days away
- EPS estimate
- −$0.53
- Revenue estimate
- $178.1M
4 of 8reports beat the EPS estimate
±4.1%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 11, 2026 | −$0.12 est −$0.05 | — | −1.3% |
| Nov 4, 2025 | $0.05 est −$0.10 | $133.0M est $140.9M | −1.1% |
| Aug 6, 2025 | −$0.12 est −$0.31 | $127.8M est $130.1M | +15.4% |
| May 6, 2025 | −$0.30 est −$0.48 | $111.6M est $98.40M | −6.6% |
| Feb 26, 2025 | −$0.49 est −$0.25 | $99.41M est $96.64M | −5.9% |
| Nov 4, 2024 | −$0.30 est −$0.45 | — | +0.8% |
| Aug 7, 2024 | −$0.52 est −$0.47 | $77.88M est $75.25M | +1.8% |
| May 8, 2024 | −$0.54 est −$0.48 | $69.22M est $70.17M | −0.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Mirum Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Mirum Pharmaceuticals is $138.21, +57.1% from the last close, from 10 firms rating the stock in the last 90 days.
$138.21consensus 12-month target, +57.1% from the last close
Now $87.96Avg $138.21
Low $118High $195
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 28 | H.C. Wainwright | $195 | +121.7% |
| Sep 10 | Citi | $145 | +64.8% |
| Aug 20 | H.C. Wainwright | $140 | +59.2% |
| Aug 11 | J.P. Morgan | $118 | +34.2% |
| Aug 10 | TD Cowen | $140 | +59.2% |
+9.7%average 20-day move after past Buying readings
−6.0%average move over the next 20 trading days in the last 5 years
±4.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Mirum Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Mirum Pharmaceuticals averaged −6.0% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.3% | 1 of 5 |
| Next 10 trading days | −6.3% | 1 of 5 |
| Next 15 trading days | −5.5% | 2 of 5 |
| Next 20 trading days | −6.0% | 2 of 5 |
| Next 30 trading days | −5.0% | 1 of 5 |
For scale, MIRM’s typical 20-trading-day move in either direction is about 8.7%.
Mirum Pharmaceuticals market cap and key statistics
Mirum Pharmaceuticals’s market cap is $5.36B and revenue of $618.1M over the last twelve months.
Valuation
- Market cap
- $5.36B
- Forward P/E
- 166.7
- EPS, TTM
- −$14.09
- Gekko Fair Value
- $115.95
Trading
- Volume
- 1.24M
- Avg volume, 20 days
- 712,292
- 52-week high
- $130.00
- 52-week low
- $63.23
- Shares outstanding
- 64.93M
Financials
- Revenue, TTM
- $618.1M
- Profit margin
- -139.2%
- Return on equity
- -703%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.49
- Typical daily move
- ±4.7%
- Typical 20-day move
- ±8.7%
Mirum Pharmaceuticals stock news this week
Coverage of Mirum Pharmaceuticals this week reads positive: 2 positive, 1 neutral and 0 negative headlines.
- Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta TranscriptSeeking Alpha, Sep 28
- MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder TherapyZacks Investment Research, Sep 28
- Mirum's liver infection drug lowers virus levels in late-stage studyReuters, Sep 28
- Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta VirusBusiness Wire, Sep 28
- Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026Business Wire, Sep 27
- Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Has Average Target Price of $137.31Defense World, Sep 26
Mirum Pharmaceuticals peers
Mirum Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Mirum Pharmaceuticals stock FAQ
What is Mirum Pharmaceuticals’s market cap?
Mirum Pharmaceuticals’s market cap is $5.36B at the Sep 28, 2026 close of $87.96, with 64.93M shares outstanding.
What is the Mirum Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Mirum Pharmaceuticals is $138.21, +57.1% from the last close. Of the 10 firms that rated the stock in the last 90 days, 10 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Mirum Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Mirum Pharmaceuticals is undervalued: the Sep 28, 2026 close of $87.96 is 24.1% below Gekko Fair Value of $115.95. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Mirum Pharmaceuticals report earnings next?
Mirum Pharmaceuticals is expected to report on Nov 3, 2026, after the market closes (35 days away). Analysts expect earnings of −$0.53 per share on revenue of $178.1M. Mirum Pharmaceuticals beat the earnings estimate in 4 of its last 8 reports, moving 4.1% on average across the report.
What is Mirum Pharmaceuticals’s 52-week high and low?
Mirum Pharmaceuticals’s 52-week high is $130.00 and its 52-week low is $63.23; it closed at $87.96 on Sep 28, 2026, +19.6% over the past year.
Is Mirum Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Mirum Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.